Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24610
Abstract: We hypothesized that the Oncotype Dx® 21‐gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers. read more here.
Keywords: gene assay; breast; assay core; using gene ... See more keywords
Characterization of a reliable cell-based reporter gene assay for measuring bioactivities of therapeutic anti-interleukin-23 monoclonal antibodies.
Sign Up to like & getrecommendations! Published in 2020 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2020.106647
Abstract: Environmental disturbances may result in dysregulation of interleukin-23 (IL-23), which is a crucial modulator of immunity. Several therapeutic monoclonal antibodies (mAbs) have been developed for treating IL-23-related autoimmune inflammation, such as ustekinumab, guselkumab, tildrakizumab, and… read more here.
Keywords: gene assay; reporter gene; monoclonal antibodies; cell based ... See more keywords
Development and validation of a novel reporter gene assay for determination of recombinant human thrombopoietin.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107982
Abstract: Recombinant human thrombopoietin (rhTPO) was approved by the National Medical Products Administration in 2010 for the treatment of thrombocytopenia in patients with immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia. Nevertheless, no method for determining rhTPO bioactivity… read more here.
Keywords: reporter; recombinant human; gene assay; reporter gene ... See more keywords
The clinician’s perspective on the 21-gene assay in early breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Oncotarget"
DOI: 10.18632/oncotarget.28148
Abstract: Most patients with early HR+ and HER2- breast cancer receive a hormone therapy; the clinical question still open is how to identify patients who can really benefit from adjuvant chemotherapy. The accurate identification of these… read more here.
Keywords: breast; breast cancer; treatment; gene assay ... See more keywords